Alerts
Myeloma Patients May Not Need Treatment Forever
The ENDURANCE trial found no overall survival benefit from indefinite lenalidomide maintenance compared with stopping after two years in standard-risk, newly diagnosed multiple myeloma patients who did not undergo transplant. This is a de-escalation story with real cost and quality-of-life consequences.
Brain-Bleed Care Still Has a Last-Mile Problem
Hepatitis A Shows What Happens When Water Systems Fail People
Ebola Funding Finally Moves. The Virus Has Already Moved Faster.
Ebola Modelling Shows the Outbreak May Be Bigger Than the Count
Court Fight Over ACIP Turns Vaccine Advice Into an Access Risk
Surviving Cancer Is Not the Same as Being Recovered
Tourette Care May Finally Get a New FDA Test
Hantavirus Quarantine Turns Travel Health Into a Civil-Liberties Test
Narcolepsy Treatment Starts Targeting the Cause
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.